IRF2 and hepatocellular carcinoma: In several human malignancies, the differential expression of IRF-2 had been defined between tumors and adjacent non-cancerous tissues, such as breast [13], esophageal squamous cell [14], pancreatic [15] and hepatocellular cancer (HCC) [16], which was associated with clinical features and patient survival.